Literature DB >> 1942267

What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma.

A Herrlinger1, K M Schrott, G Schott, A Sigel.   

Abstract

In a prospective study of 511 patients we compared the data of 320 who underwent systematically extended dissection of the regional lymph nodes with data of 191 who underwent only facultative dissection of the lymph nodes, which means that no lymph nodes had been removed or only a few were taken for staging purposes. Only patients without distant metastases and who were less than 72 years old were included. All patients were treated with a transabdominal approach. The incidence of positive nodes in the patients with systematically extended lymphadenectomy was 17.5% and for patients with facultative lymphadenectomy it was 10%. Survival rates of patients with facultative lymphadenectomy were 58% after 5 years and 40.9% after 10 years, compared to 66% and 56.1%, respectively, for patients with systematically extended lymphadenectomy (p less than 0.01). Patients with stage pT1-2 (Robson stage I) and pT3aN0M0 (Robson stage II) tumor obviously had the highest benefits with extended lymphadenectomy. Operative mortality was less than 1% after systematically extended lymphadenectomy and 3.8% after facultative lymphadenectomy. We conclude from our data that the systematic and extended lymphadenectomy improves the prognosis of patients with renal cell carcinoma without any additional operative risks.

Entities:  

Mesh:

Year:  1991        PMID: 1942267     DOI: 10.1016/s0022-5347(17)38052-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  [Lymph node dissection in patients with renal cell carcinoma].

Authors:  T Ebert; D Schnell; L Weissbach
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

2.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

4.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

5.  Surgical approach and the use of lymphadenectomy and adrenalectomy among patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Christopher P Filson; David C Miller; Joanne S Colt; Julie Ruterbusch; W Marston Linehan; Wong-Ho Chow; Kendra Schwartz
Journal:  Urol Oncol       Date:  2011-03-17       Impact factor: 3.498

6.  Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Stephen J Freedland; Jean B Dekernion
Journal:  Rev Urol       Date:  2003

7.  Lymph node dissection in patients with kidney cancer: when is it indicated?

Authors:  Ganesh S Palapattu; Hyung L Kim; Arie S Belldegrun
Journal:  Rev Urol       Date:  2003

Review 8.  Oncological and renal medical importance of kidney-sparing surgery.

Authors:  Paul Russo
Journal:  Nat Rev Urol       Date:  2013-03-05       Impact factor: 14.432

9.  Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?

Authors:  Stephen H Culp; Christopher G Wood
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

10.  A comparison of two different incisional approaches in the surgical treatment of renal cell carcinomas.

Authors:  M Abdurrahim Imamoğlu; Hasan Bakirtaş; Levent Sağnak; Can Tuygun; Hamit Ersoy
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.